XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.21.1

Collaborative Arrangements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2021 |  | 2020 |  |  |  |
Alliance revenue - Lynparza | $ | 228 |  |  | $ | 145 |  |  |  |  |
Alliance revenue - Koselugo | 5 |  |  | — |  |  |  |  |
Total alliance revenue | $ | 233 |  |  | $ | 145 |  |  |  |  |
Cost of sales (1) | 42 |  |  | 28 |  |  |  |  |
Selling, general and administrative | 40 |  |  | 33 |  |  |  |  |
Research and development | 29 |  |  | 36 |  |  |  |  |
($ in millions) | March 31, 2021 |  | December 31, 2020 |  |  |  |
Receivables from AstraZeneca included in Other current assets | $ | 236 |  |  | $ | 215 |  |  |  |  |
Payables to AstraZeneca included in Accrued and other current liabilities (2) | 417 |  | 423 |  |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2021 |  | 2020 |  |  |  |
Alliance revenue - Lenvima | $ | 130 |  |  | $ | 128 |  |  |  |  |
Cost of sales (1) | 47 |  |  | 35 |  |  |  |  |
Selling, general and administrative | 23 |  |  | 11 |  |  |  |  |
Research and development | 64 |  |  | 64 |  |  |  |  |
($ in millions) | March 31, 2021 |  | December 31, 2020 |  |  |  |
Receivables from Eisai included in Other current assets | $ | 153 |  |  | $ | 157 |  |  |  |  |
Payables to Eisai included in Accrued and other current liabilities (2) | 300 |  |  | 335 |  |  |  |  |
Payables to Eisai included in Other Noncurrent Liabilities (3) | 300 |  |  | 600 |  |  |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone and future option payments. (3) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2021 |  | 2020 |  |  |  |
Alliance revenue - Adempas | $ | 74 |  |  | $ | 53 |  |  |  |  |
Net sales of Adempas recorded by Merck | 55 |  |  | 56 |  |  |  |  |
Total sales | $ | 129 |  |  | $ | 109 |  |  |  |  |
Cost of sales (1) | 189 |  |  | 28 |  |  |  |  |
Selling, general and administrative | 32 |  |  | 15 |  |  |  |  |
Research and development | 7 |  |  | 25 |  |  |  |  |
($ in millions) | March 31, 2021 |  | December 31, 2020 |  |  |  |
Receivables from Bayer included in Other current assets | $ | 68 |  |  | $ | 65 |  |  |  |  |
Payables to Bayer included in Other Noncurrent Liabilities (2) | 400 |  |  | — |  |  |  |  |
(1) Includes amortization of intangible assets. Amount in the first quarter of 2021 includes $153 million of cumulative amortization as noted above. (2) Represents accrued milestone payment.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration